



Considerations for Recommendations

ACIP HPV Vaccines Work Group

Lauri Markowitz, MD
Division of Viral Diseases

Advisory Committee on Immunization Practices
June 24, 2016

Considerations for recommendations – 2 dose HPV vaccination schedules

- This presentation addresses general approach for recommendations
- Specific wording for special situations, minimal intervals, and other issues not addressed

Current recommendations for HPV vaccination in the United States

- ACIP recommends routine vaccination at age 11 or 12 years*
- ACIP also recommends vaccination for females aged 13 through age 26 for males aged 13 through age 21 not previously vaccinated
- Vaccination recommended for immunocompromised persons (including persons HIV-infected) and for men who have sex with men through age 26
- 3-dose schedule (0, 1–2, 6 months)
- Vaccines
 - 2vHPV, 4vHPV or 9vHPV for females
 - 4vHPV or 9vHPV for males

*vaccination series can be started at age 9 years

Draft proposed recommendations

- ACIP recommends routine HPV vaccination at age 11 or 12 years*
- A 2-dose schedule is recommended.⁺ The second dose should be administered **6 to 12 months** after the first dose.

*Vaccination series can be started at age 9 years

⁺A 3-dose series can be given (0, 1–2, 6 months)

Note: Blue text indicates further discussion needed with WG and ACIP

Draft proposed recommendations

- Vaccination is also recommended for females through 26 years and for males through 21 years not previously vaccinated
- For persons initiating vaccination before their 15th birthday, ACIP recommends 2 doses of HPV vaccine. The second dose should be administered **6 to 12 months** after the first dose.*
- For persons initiating the vaccination series after their 15th birthday, ACIP recommends 3 doses of HPV vaccine. The second dose should be administered 1 to 2 months after the first dose and the third dose 6 months after the first dose (0, 1–2, and 6 month schedule).

*A 3-dose series can be given (0, 1–2, 6 months)

Note: Blue text indicates further discussion needed with WG and ACIP

Draft proposed recommendations

If vaccination series started before 15th birthday

- Persons who started the HPV vaccination series with 9vHPV, 4vHPV or 2vHPV and
 - received 2 doses \geq 6 months apart, are considered adequately vaccinated
 - received 2 doses $<$ 6 months apart, should receive a third dose \geq 6 months after dose 1
 - received 1 dose, should receive a second dose \geq 6 months after dose 1

Draft proposed recommendations

If vaccination series started after 15th birthday

- Persons who started the HPV vaccination series with 9vHPV, 4vHPV or 2vHPV and
 - received 3 doses with the third dose \geq 6 months after dose 1, are considered adequately vaccinated
 - received 2 doses, should receive a third dose \geq 6 months after dose 1
 - received 1 dose, should complete a 3-dose series (0, 1–2, 6 months)

Draft proposed recommendation

Special populations

- For immunocompromised patients of any age, including those with HIV infection, ACIP recommends 3 doses of HPV vaccine (0, 1–2, 6 months)

Issues for discussion

- Support for a 2-dose recommendation
- ACIP recommends “HPV vaccine” or “9vHPV”
- Recommendations for those starting series before 15th birthday
 - Specify intervals between doses (0, 6 months or 0, 12 months), range (6 to 12 months) or minimal interval (at least 6 months)?
 - If a 2-dose schedule is recommended, should there be an option for a 3-dose schedule?

Acknowledgments

ACIP Members

Allison Kempe (Chair)
Cynthia Pellegrini
Jose Romero

Ex Officio Members

Carolyn Deal (NIH) A
Bruce Gellin (NVPO)
Jeff Roberts (FDA)
Sixun Yang (FDA)

Liaison Representatives

Shelley Deeks (NACCI)
Sandra Fryhofer (ACP)
Linda Eckert (COG)
Amy Middleman (SAHM)
Chris Nyquist (AAP)
Sean O'Leary (PIDS)
Margot Savoy (AAFP)
Patricia Whitley-Williams (NMA)
Jane Zucker (AIM)

Consultants

Joseph Bocchini
Tamera Coyne-Beasley
John Douglas
Sam Katz
Aimee Kreimer (NCI)
Debbie Saslow (ACS)
Rodney Willoughby

CDC

Jorge Arana
Harrell Chesson
Robin Curtis
Julianne Gee
Lauri Markowitz
Elissa Meites
Jeanne Santoli
Mona Saraiya
Shannon Stokley
Lakshmi Sukumaran
Elizabeth Unger

Thank You

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

